Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.

ABSTRACT: Efficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of response to immunotherapy and to design safer and more efficient strategies. In addition to classical tumor-associated antigens identified during the last decades, implementation of next-generation sequencing methodologies is enabling the identification of neoantigens (neoAgs) arising from mutations, leading to the development of new neoAg-directed therapies. Moreover, there are numerous non-classical tumor antigens originated from other sources and identified by new methodologies. Here, we review the

SUBMITTER: Aparicio B 

PROVIDER: S-EPMC10863374 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature